Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma
BackgroundDisulfidptosis is an emerging type of programmed cell death related to ROS accumulation and aberrant disulfide bond formation. Multiple myeloma (MM) is the second most prevalent hematologic malignancy characterized by a high synthesis rate of…